Eisai Co., Ltd. and Nuvation Bio Inc. have announced a long-term exclusive license and collaboration agreement for the drug taletrectinib. Already approved for advanced non-small cell lung cancer (NSCLC) in the U.S, China, and Japan, under the new agreement, Eisai will now have exclusive development, registration and commercialization rights for taletrectinib, in Europe and several other regions. The territories include […]
